Merger extends R&D capabilities and product expertise; expands customer base
AUSTIN (November 15, 2006) — Rules-Based Medicine, Inc. (RBM), the leading multiplexed biomarker testing laboratory for the life sciences industry, announced today that it has merged with Lake Placid, New York-based Multiplex Biosciences, Inc. to extend its research and development capability in multiplexed assay product development and expand its customer base.
The combined company will operate under the Rules-Based Medicine name with headquarters located in Austin, Texas. Multiplex Bioscience employees will continue to work in Lake Placid, with immediate growth planned at that facility.
“With the development of over 200 new assays scheduled in the next 18 months, Multiplex Bioscience is a strategically important addition to Rules-Based Medicine,” said Craig Benson, President and CEO of Rules-Based Medicine. “RBM is in high-growth mode and we value the unique capabilities and expertise that the world-class Multiplex Bioscience scientists bring to our team as we accelerate our product development efforts.”
“We are pleased to join forces with the Rules-Based Medicine team,” said Dominic Eisinger, PhD., president of Multiplex Biosciences. “Its customer base and growth are a testament to its leadership position. This merger opens opportunities for us to benefit from RBM’s reinvestment and business growth strategy and continue our advancements in multiplex assay product development in Lake Placid.”
About Multiplex Biosciences
Multiplex Biosciences, Inc. (www.multiplexbiosciences.com) provides contract multiplex immunoassay development, validation and manufacturing services to pharmaceutical companies, biotech firms and academic research institutions, and develops its own line of multiplex products. The company was founded in 2006 and is wholly owned by Dominic Eisinger and Laurie Stephen, former senior managers at Upstate Cell Signaling Solutions, now part of Millipore Corporation.
About Rules-Based Medicine
Rules-Based Medicine (RBM) provides comprehensive protein biomarker products and services centered on its Multi-Analyte Profiling (MAP) technology. Its service platform (RodentMAP® and HumanMAP®) provides pre-clinical and clinical researchers with reproducible, quantitative, multiplexed immunoassay data for hundreds of proteins cost-effectively in multiple species, and from a small sample volume. The Company also offers innovative and proprietary ex vivo testing systems such as TruCulture™, the first fully-closed, reproducible whole blood culture system. RBM is actively developing multiplex diagnostic tests to detect the presence of complex diseases and conditions in areas of unmet medical need such as neuropsychiatry, nephrology, immunology and cardiology. More information about RBM is located at www.rbmmaps.com.